Fintel reports that on September 25, 2023, Morgan Stanley downgraded their outlook for Vaccitech plc – ADR (NASDAQ:VACC) from Overweight to Equal-Weight.
Analyst Price Forecast Suggests 637.35% Upside
As of August 31, 2023, the average one-year price target for Vaccitech plc – ADR is 12.24. The forecasts range from a low of 7.07 to a high of $15.75. The average price target represents an increase of 637.35% from its latest reported closing price of 1.66.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Vaccitech plc – ADR is 2MM, a decrease of 84.80%. The projected annual non-GAAP EPS is -2.36.
What is the Fund Sentiment?
There are 16 funds or institutions reporting positions in Vaccitech plc – ADR. This is an increase of 1 owner(s) or 6.67% in the last quarter. Average portfolio weight of all funds dedicated to VACC is 1.60%, a decrease of 24.78%. Total shares owned by institutions decreased in the last three months by 3.54% to 9,855K shares.
What are Other Shareholders Doing?
M&g Investment Management holds 5,197K shares representing 13.49% ownership of the company. No change in the last quarter.
Alphabet holds 1,514K shares representing 3.93% ownership of the company. No change in the last quarter.
SC CHINA HOLDING holds 1,420K shares representing 3.69% ownership of the company. No change in the last quarter.
DC Funds holds 642K shares representing 1.67% ownership of the company. No change in the last quarter.
BlueCrest Capital Management holds 543K shares representing 1.41% ownership of the company. No change in the last quarter.
Vaccitech Background Information
(This description is provided by the company.)
Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company’s proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable tolerability profiles and without the ability to replicate in humans. The combination of a ChAdOx prime treatment with subsequent MVA boost has consistently generated significantly higher magnitudes of CD8+ T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.
This article originally appeared on Fintel
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
